Sarepta downgraded to Market Perform from Outperform at JMP Securities JMP Securities downgraded Sarepta due to valuation and expectations pivotal data and approval of its Duchenne Muscular Dystrophy drug will take longer than expected.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sarepta said to cancel appearance at Needham conference Sarepta cancelled its appearance at Needham's conference tomorrow due to "other obligations," a re-tweet by The Street's Adam Feuerstein says, citing a confirmation from the company. Shares of Sarepta moved up 23c to $23.37 following circulation of the tweet.